Tech & Pharma
Recent News
-
Ancient Fossil Fishes Had ‘Six Pack’ Abs, Study June 17, 2013 08:06
-
Shenzhou-10 Successfully Docks With Tiangong Space Lab June 17, 2013 08:06
-
Oldest Man In History Dies In Kyoto, Japan At 116 June 17, 2013 08:06
-
BioLineRx, CTTQ To Commercialize Hepatitis C Drug, BL-8030, In China June 17, 2013 08:06
-
Fluorescent Protein From Unagi Eel To Revolutionize Liver Clinical Test June 17, 2013 08:06
-
BMS, Simcere Pharma To Co-Develop Orencia® SC In China June 17, 2013 08:06
-
Chemical Used In PVC Production Linked To Kidney Stones June 17, 2013 08:06
-
Clinical Study Blocks Protein To Treat Spinal Cord Injury June 17, 2013 08:06
-
MIT Researchers Study Pandemic Potential Of H5N1 & H7N9 Virus June 17, 2013 08:06
-
Researchers Identify Gene For Aggressive Liver Cancer June 17, 2013 08:06
Tech & Pharma
BioLineRx, CTTQ To Commercialize Hepatitis C Drug, BL-8030, In China
BioLineRx has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharma to commercialize BL-8030 in China.
BMS, Simcere Pharma To Co-Develop Orencia® SC In China
BMS and Simcere will co-develop and co-commercialize the subcutaneous formulation of Orencia® for the treatment of rheumatoid arthritis in China.
BASF To Invest €10 billion In Asia Pacific Region
Global chemical company, BASF, plans to invest €10 billion in Asia from 2013-2020, as part of the company’s Asia Pacific strategy.
Fujifilm & Dr. Reddy’s Call Off Generic Drugs Joint Venture In Japan
FUJIFILM and Dr. Reddy’s Laboratories have terminated an MOU to enter into a joint venture for the Japanese generics drugs market.
PAREXEL Opens Office In Shenyang, China
PAREXEL International Corporation opened in May a new office in Shenyang, China to support client demand for clinical development capabilities in the region.
Merck & BeiGene To Co-Develop 2nd Gen BRAF Inhibitor
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
EBOS Group Limited Acquires Australian Pharma Distributor, Symbion
EBOS Group Limited announced this week details of a NZ$1.1 billion acquisition of Australia’s Symbion.
ASLAN’s Pan-HER Inhibitor Shows Positive Data In Gastric Cancer PhII Study
ASLAN Pharma announced this week positive data with ASLAN001 in a gastric cancer Phase II study.
Japan Launches Public-Private Partnership To Fight Neglected Diseases
The Global Health Innovative Technology Fund, a new public-private partnership, is taking Japanese R&D to the global fight against infectious disease.
Amgen & Astellas Enter Into Japan Alliance
Amgen and Astellas Pharma Inc. today announced a strategic alliance to co-develop and co-commercialize new medicines in Japan.